The stock of Sophiris Bio Inc (NASDAQ:SPHS) is a huge mover today! About 3.36 million shares traded hands or 372.90% up from the average. Sophiris Bio Inc (NASDAQ:SPHS) has risen 109.30% since April 26, 2016 and is uptrending. It has outperformed by 104.04% the S&P500.
The move comes after 6 months positive chart setup for the $81.29M company. It was reported on Nov, 29 by Barchart.com. We have $3.24 PT which if reached, will make NASDAQ:SPHS worth $6.50 million more.
Analysts await Sophiris Bio Inc (NASDAQ:SPHS) to report earnings on March, 22. They expect $-0.09 earnings per share, up 40.00% or $0.06 from last year’s $-0.15 per share. After $-0.15 actual earnings per share reported by Sophiris Bio Inc for the previous quarter, Wall Street now forecasts -40.00% EPS growth.
Sophiris Bio Inc (NASDAQ:SPHS) Ratings Coverage
Out of 3 analysts covering Sophiris Bio (NASDAQ:SPHS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Sophiris Bio has been the topic of 3 analyst reports since August 30, 2016 according to StockzIntelligence Inc. The stock of Sophiris Bio Inc (NASDAQ:SPHS) has “Overweight” rating given on Tuesday, August 30 by Piper Jaffray. Roth Capital initiated Sophiris Bio Inc (NASDAQ:SPHS) rating on Thursday, September 15. Roth Capital has “Buy” rating and $8.0 price target. The firm earned “Buy” rating on Thursday, September 15 by TH Capital.
According to Zacks Investment Research, “Sophiris Bio Inc. operates as a biopharmaceutical company. The Company is developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate). It has operations based in San Diego. Sophiris Bio Inc. is based in Canada.”
Insitutional Activity: The institutional sentiment increased to 2.33 in Q2 2016. Its up 1.56, from 0.77 in 2016Q1. The ratio increased, as 8 funds sold all Sophiris Bio Inc shares owned while 5 reduced positions. 5 funds bought stakes while 5 increased positions. They now own 1.50 million shares or 31.22% less from 2.18 million shares in 2016Q1.
Moreover, Vanguard Grp has 0% invested in Sophiris Bio Inc (NASDAQ:SPHS) for 331,000 shares. Airain Limited has 32,017 shares for 0% of their US portfolio. Fincl Bank Of America De accumulated 0% or 1,222 shares. The California-based Palo Alto Investors Ltd Llc has invested 0.08% in Sophiris Bio Inc (NASDAQ:SPHS). Citadel Ltd Company reported 49,176 shares or 0% of all its holdings. Kcg reported 17,013 shares or 0% of all its holdings. Rock Springs Mgmt Limited Partnership owns 490,000 shares or 0.08% of their US portfolio. State Bank Of Montreal Can has 1,632 shares for 0% of their US portfolio. Ladenburg Thalmann Service Inc has 0% invested in the company for 600 shares. Deutsche State Bank Ag has invested 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS). Morgan Stanley has 0% invested in the company for 225 shares. Moreover, Fny Managed Accounts Lc has 0% invested in Sophiris Bio Inc (NASDAQ:SPHS) for 7,556 shares. Jane Street Ltd Liability Com, a New York-based fund reported 27,176 shares. Wells Fargo & Mn holds 0% or 3,800 shares in its portfolio. Creative Planning reported 900 shares or 0% of all its holdings.
More notable recent Sophiris Bio Inc (NASDAQ:SPHS) news were published by: Prnewswire.com which released: “Sophiris Bio to Present at 28th Annual Piper Jaffray Healthcare Conference” on November 22, 2016, also Prnewswire.com with their article: “Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business …” published on November 09, 2016, Prnewswire.com published: “Sophiris Bio Inc. Announces Closing of Public Offering of $5000000” on May 11, 2016. More interesting news about Sophiris Bio Inc (NASDAQ:SPHS) were released by: Prnewswire.com and their article: “Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as …” published on May 05, 2016 as well as Prnewswire.com‘s news article titled: “Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering” with publication date: May 06, 2016.
SPHS Company Profile
Sophiris Bio Inc., incorporated on May 1, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on developing products for the treatment of urological diseases. The Firm is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.